Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Allogene Therapeutics Inc...

    NASDAQ: ALLO · Real-Time Price · USD
    1.34
    -0.06 (-4.29%)
    At close: Jun 13, 2025, 3:59 PM
    1.33
    -0.74%
    After-hours: Jun 13, 2025, 07:07 PM EDT

    Allogene Therapeutics Statistics

    Share Statistics

    Allogene Therapeutics has 218.73M shares outstanding. The number of shares has increased by 4.06% in one year.

    Shares Outstanding

    n/a
    		 218.73M

    Shares Change (YoY)

    n/a
    		 4.06%

    Shares Change (QoQ)

    n/a
    		 3.62%

    Owned by Institutions (%)

    n/a
    		 90.19%

    Shares Floating

    n/a
    		 149.47M

    Failed to Deliver (FTD) Shares

    n/a
    		 472,701

    FTD / Avg. Volume

    n/a
    		 14.19%

    Short Selling Information

    The latest short interest is 24.57M, so 11.23% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 24.57M

    Short % of Shares Out

    n/a
    		 11.23%

    Short % of Float

    n/a
    		 13.6%

    Short Ratio (days to cover)

    n/a
    		 10.4

    Valuation Ratios

    The PE ratio is -1.61 and the forward PE ratio is -1.42. Allogene Therapeutics's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -1.61

    Forward PE

    n/a
    		 -1.42

    PS Ratio

    n/a
    		 18861.32

    Forward PS

    n/a
    		 0.8

    PB Ratio

    n/a
    		 0.98

    P/FCF Ratio

    n/a
    		 -2.06

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Allogene Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.54, with a Debt / Equity ratio of 0.21.

    Current Ratio

    n/a
    		 8.54

    Quick Ratio

    n/a
    		 8.54

    Debt / Equity

    n/a
    		 0.21

    Debt / EBITDA

    n/a
    		 -0.37

    Debt / FCF

    n/a
    		 -0.45

    Interest Coverage

    n/a
    		 -1509.39

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $97.35

    Profits Per Employee

    n/a
    		 $-1,139,778.76

    Employee Count

    n/a
    		 226

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 443K

    Effective Tax Rate

    n/a
    		 -0.17%

    Stock Price Statistics

    The stock price has increased by -42.98% in the last 52 weeks. The beta is 0.31, so Allogene Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.31

    52-Week Price Change

    n/a
    		 -42.98%

    50-Day Moving Average

    n/a
    		 1.34

    200-Day Moving Average

    n/a
    		 2.03

    Relative Strength Index (RSI)

    n/a
    		 51.89

    Average Volume (20 Days)

    n/a
    		 3,331,385

    Income Statement

    In the last 12 months, Allogene Therapeutics had revenue of 22K and earned -257.59M in profits. Earnings per share was -1.32.

    Revenue

    n/a
    		 22K

    Gross Profit

    n/a
    		 -192.28M

    Operating Income

    n/a
    		 -273.2M

    Net Income

    n/a
    		 -257.59M

    EBITDA

    n/a
    		 -243.33M

    EBIT

    n/a
    		 -256.97M

    Earnings Per Share (EPS)

    n/a
    		 -1.32
    Full Income Statement

    Balance Sheet

    The company has 75.22M in cash and 90.76M in debt, giving a net cash position of -15.54M.

    Cash & Cash Equivalents

    n/a
    		 75.22M

    Total Debt

    n/a
    		 90.76M

    Net Cash

    n/a
    		 -15.54M

    Retained Earnings

    n/a
    		 -1.82B

    Total Assets

    n/a
    		 507.98M

    Working Capital

    n/a
    		 261.55M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -200.3M and capital expenditures -694K, giving a free cash flow of -200.99M.

    Operating Cash Flow

    n/a
    		 -200.3M

    Capital Expenditures

    n/a
    		 -694K

    Free Cash Flow

    n/a
    		 -200.99M

    FCF Per Share

    n/a
    		 -1.03
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -1241813.64% and -1170863.64%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -1241813.64%

    Pretax Margin

    n/a
    		 -1168850%

    Profit Margin

    n/a
    		 -1170863.64%

    EBITDA Margin

    n/a
    		 -1106031.82%

    EBIT Margin

    n/a
    		 -1241813.64%

    FCF Margin

    n/a
    		 -913609.09%

    Dividends & Yields

    ALLO does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ALLO is $9, which is 571.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $9

    Price Target Difference

    n/a
    		 571.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 9
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -4.98

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist